RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 Regorafenib Improves OS in Asian Patients with mCRC after Previous Failure with Standard Therapy
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 22
SP 17
OP 18
DO 10.1177/155989771422015
UL http://mdc.sagepub.com/content/14/22/17.2.abstract
AB The oral multikinase inhibitor regorafenib targets multiple pathways involved in tumor development and progression. In the CORRECT study [Grothey A et al. Lancet. 2013], treatment with regorafenib improved overall survival (OS) in patients with metastatic colorectal cancer (mCRC) disease progression after standard therapies (HR, 0.77; 95% CI, 0.64 to 0.94; 1-sided p?=?.0052). This article presents the results from the Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy study [CONCUR; NCT01584830], a trial examining the efficacy and safety of regorafenib in a larger group of Asian patients with mCRC.